User profiles for Maria Carmela Piccirillo
 | Maria Carmela PiccirilloMD, National Cancer Institute, Napoli Verified email at istitutotumori.na.it Cited by 5312 |
The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer …
5505 Background: A longer PFI is associated with better outcomes in patients with OC. It has
long been hypothesized that artificially prolonging PFI by introducing a non-platinum based …
long been hypothesized that artificially prolonging PFI by introducing a non-platinum based …
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
…, L Selvaggi, S Signoriello, MC Piccirillo… - The lancet …, 2014 - thelancet.com
Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …
[PDF][PDF] Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials
M Di Maio, C Gallo, NB Leighl, MC Piccirillo… - Journal of Clinical …, 2015 - iris.unito.it
Purpose Information about symptomatic toxicities of anticancer treatments is not based on
direct report by patients, but rather on reports by clinicians in trials. Given the potential for …
direct report by patients, but rather on reports by clinicians in trials. Given the potential for …
[PDF][PDF] First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies …
[HTML][HTML] Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods …
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods …
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current …
A Morabito, MC Piccirillo, F Falasconi, G De Feo… - The …, 2009 - academic.oup.com
Learning Objectives Evaluate the mechanism of action of vandetanib in the care of patients
with thyroid cancer. Analyze the current status of clinical development and early clinical …
with thyroid cancer. Analyze the current status of clinical development and early clinical …
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open …
…, V Salutari, C Ricci, G Daniele, MC Piccirillo… - The Lancet …, 2015 - thelancet.com
Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer.
Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of …
Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of …
[HTML][HTML] Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional …
…, M Silletta, L D'Onofrio, C Spoto, MC Piccirillo… - PloS one, 2015 - journals.plos.org
Background The European Association for the Study of the Liver (EASL) criteria and the
modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to …
modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to …
[HTML][HTML] Immunotherapy in small cell lung cancer
…, N Martucci, A La Rocca, G De Luca, MC Piccirillo… - Cancers, 2020 - mdpi.com
Simple Summary Small cell lung cancer (SCLC) accounts for about 15% of lung cancers and
it has limited therapeutic options and poor prognosis. There has been no real progress for …
it has limited therapeutic options and poor prognosis. There has been no real progress for …
[HTML][HTML] Angiogenesis inhibitors in NSCLC
…, C Sandomenico, N Normanno, MC Piccirillo… - International Journal of …, 2017 - mdpi.com
Angiogenesis is a complex biological process that plays a relevant role in sustaining the
microenvironment, growth, and metastatic potential of several tumors, including non-small cell …
microenvironment, growth, and metastatic potential of several tumors, including non-small cell …